A new study suggests that ABCA1, a protein involved in cholesterol transport in the brain, may play an important role in the development of the condition and could offer a potential target for future treatments. Parkinson’s disease (PD) is a progressive neurodegenerative disorder that damages dopamine-producing neurons in a brain region called the substantia nigra. It commonly causes tremors, muscle stiffness, slowed movements and balance difficulties. Although no cure currently exists, medications can help manage its symptoms. Researchers at Nanjing Medical University found that ABCA1 may contribute to cholesterol accumulation and neuronal damage associated with the disease. Published in Nature Neuroscience, the study provides new insights into the role of cholesterol imbalance in Parkinson’s progression.
How Does Cholesterol Contribute to Parkinson’s Disease?
Previous studies have linked abnormal cholesterol accumulation in the brain to Parkinson’s disease. To investigate this connection, researchers examined human brain tissue, mouse models and laboratory-grown cells, focusing on ABCA1, a protein that regulates cholesterol transport. They found increased ABCA1 expression in the substantia nigra of people with Parkinson’s and in mouse models. Further analysis showed that ABCA1 in astrocytes, specialised brain cells, promoted excessive cholesterol release, contributing to its accumulation in neurons. Meanwhile, ABCA1 activity in neurons helped transport cholesterol into lysosomes, the cellular compartments responsible for breaking down and recycling waste materials.
Cholesterol Buildup May Damage Brain Cells
The researchers found that excessive cholesterol accumulation inside lysosomes disrupted cellular recycling processes and contributed to the buildup of alpha-synuclein, a protein associated with Parkinson’s disease. Normally, alpha-synuclein helps regulate communication between nerve cells. However, when it folds abnormally and forms clumps, it can contribute to neuronal damage. These findings suggest that ABCA1-related cholesterol imbalance may play an important role in Parkinson’s disease.
Blocking ABCA1 Shows Promising Results in Mice
To explore its potential as a treatment target, researchers used genetic techniques to reduce ABCA1 production in mouse brains. The results showed that reducing ABCA1 activity helped protect dopamine-producing neurons and improved Parkinson’s-like movement problems. The team also screened different substances to identify potential ABCA1 inhibitors. One compound, magnesium citrate, reduced the loss of dopamine-producing neurons in the mouse model.
A Potential New Target for Parkinson’s Treatment
The study identifies ABCA1 as a possible target for future Parkinson’s treatments by highlighting its role in cholesterol transport and neuronal damage. However, the findings are still preliminary. The benefits of magnesium citrate have not been established in humans, and further research using additional animal models is needed to confirm its therapeutic potential. Scientists must also determine whether targeting ABCA1 can safely slow disease progression without causing unwanted effects. Overall, the findings offer new insights into the relationship between cholesterol imbalance and Parkinson’s disease and could help guide the development of future treatments, as reported by Medical Xpress.